NVX-CoV2373异源加强针针对新冠病毒变异株的免疫原性。
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.
作者信息
Lyke Kirsten E, Atmar Robert L, Dominguez Islas Clara, Posavad Christine M, Deming Meagan E, Branche Angela R, Johnston Christine, El Sahly Hana M, Edupuganti Srilatha, Mulligan Mark J, Jackson Lisa A, Rupp Richard E, Rostad Christina A, Coler Rhea N, Bäcker Martín, Kottkamp Angelica C, Babu Tara M, Dobrzynski David, Martin Judith M, Brady Rebecca C, Frenck Robert W, Rajakumar Kumaravel, Kotloff Karen, Rouphael Nadine, Szydlo Daniel, PaulChoudhury Rahul, Archer Janet I, Crandon Sonja, Ingersoll Brian, Eaton Amanda, Brown Elizabeth R, McElrath M Juliana, Neuzil Kathleen M, Stephens David S, Post Diane J, Lin Bob C, Serebryannyy Leonid, Beigel John H, Montefiori David C, Roberts Paul C
机构信息
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA.
出版信息
NPJ Vaccines. 2023 Jul 11;8(1):98. doi: 10.1038/s41541-023-00693-z.
As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ.1.1 and XBB.1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26.COV2.S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials.gov: NCT04889209.
作为一项评估同源和异源新冠病毒加强疫苗的多中心研究的一部分，我们在接种过Ad26.COV2.S、mRNA-1273或BNT162b2疫苗的成年人中，评估了单剂次接种NVX-CoV2373加强疫苗后结合抗体和假病毒中和抗体（PsVNA）反应的强度、广度和短期持久性。NVX-CoV2373作为异源加强疫苗具有免疫原性，且在第91天之前未发现安全问题。从基线（第1天）到第29天，原型D614G变体的PsVNA滴度的倍数增长最高，而最近的奥密克戎亚谱系BQ.1.1和XBB.1的倍数增长最低。接种Ad26.COV2.S疫苗的人群对所有SARS-CoV-2变体的峰值体液反应低于接种mRNA疫苗的人群。既往SARS-CoV-2感染与显著更高的基线PsVNA滴度相关，在第91天之前，相对于未感染的参与者，这些滴度一直保持在较高水平。这些数据支持使用基于蛋白质的异源加强疫苗作为mRNA或基于腺病毒的新冠病毒加强疫苗的可接受替代方案。本试验在ClinicalTrials.gov（NCT04889209）下进行。
Zotero 插件